Stockchase Opinions

Ryan Modesto CRH Medical Corp. CRH-T DON'T BUY Nov 14, 2017

Thinks management got caught off guard with the Medicare/Medicaid changes. Listening to the calls, he didn’t have a lot of confidence. Their business model is a bit broken now. With the share price and valuation so low, they are not getting as much bang for their buck now. Heading into the tax loss season, this is probably going to be one of the big targets. He would sit on the sidelines, at least until the new year.

$1.920

Stock price when the opinion was issued

biotechnology pharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

You might be interested:

COMMENT

Has been badly beaten up. In 2014, revenues were about $11 million, and are now looking at about $100 million. BV is around $.85, so it is still trading at around 3X BV. The important thing is that insiders have been selling like crazy. When this happens, that is not a good sign. Not a contrarian stock to his way of thinking.

WATCH

He was one of the first buyers. He sold half his position when it was disproportionately high and then the rest on the way down. The market has lost confidence in management, who also sold a lot of shares in the $7 range. If it broke through $3.30 on heavy volume he would take a good look but there are better options until then.

COMMENT

Had this in his Growth portfolio, and it just didn’t work out. A situation where a company gets oversold. It will probably have a good January bounce because of all the tax loss selling that has probably occurred over the last couple of weeks or months. He is having a hard time with this. Would like to support it on valuation, but in terms of execution it has issues with payor codes changing, and the revenue growth is largely beyond the company's control. They haven't handled the past year very well. He would put this in the "OK" category, but with 10,000 public companies to choose from, it is well low on his list.

COMMENT

Their business has been cut back, which is why the stock price had dropped. Feels they continue to be in the "rinse and repeat" mode. They make an acquisition, amalgamate it, bring it into their operation, and increase the business through their marketing, and then go and make another acquisition. Management feels there is lots and lots of room for them to continue this way. The stock looks like it has built a bit of a base and is trying to move higher. Suspects the worst of the news is out, and the market will probably continue to warm up to it.

BUY

He was long about a year ago. It had a rough ride but he is long again now. The valuation has become compelling. Good balance sheet and debt not a problem.

TOP PICK
This company is involved in colonoscopies and aggregates businesses in that space, mostly in the US. It trades at less than 10 times free cash-flow. He expects growth from organic tail winds in the procedure space. Acquisitions are done within existing cash flow. Yield 0%. (Analysts’ price target is $6.08)
PARTIAL BUY
A $4 stock that's chugging along. It's got a chance now and has room to move. Hold or buy a new half-position.
COMMENT
It's trending along now. Not worried about it. It'll be rangebound; it's currently right in the middle of this channel. Breaking below the range would be negative.
WEAK BUY
Perhaps sideways period is ending. Breakout, look for volume to support it. Keep in mind that $5 stocks are not being eaten up by institutional investors. As long as retail likes it, it will go up. Looks OK from his technical perspective.
WATCH
He does not own this one, despite the earnings metrics looking solid and there is no net debt. They missed on a recent quarterly earning, but not a bid deal. They are trading at 7 times cash flow and 7 times EBITDA. He would like to see the ROE improve a bit. Price momentum has picked up so he will be watching it.